太吉在帕金森病中认知功能的改善:一个元分析
Jinling Yin1, Yang Liu2, Wangang Lyu1
1School of Physical Education, Wuhan Sports University, 430079 Wuhan, Hubei, China.
Journal of integrative neuroscience
|September 21, 2023
概括
太吉 (TJ) 改善了帕金森病 (PD) 患者的认知功能. 建议定期进行TJ练习,每周两次45-60分钟,持续12周,以获得最佳益处.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 康复医学 康复医学 康复医学
背景情况:
- 帕金森病 (PD) 显著影响患者的生活质量,主要是由于认知能力下降.
- 认知功能对PD患者至关重要,因此加强认知功能的干预措施非常有价值.
- 太吉 (TJ) 已成为改善PD认知功能的潜在治疗干预措施.
结论:
- 太吉 (TJ) 对帕金森病 (PD) 患者的认知功能产生积极影响.
- 随着疾病的进展,TJ的益处可能会减少.
- 患有PD的患者可以利用TJ作为治疗干预,推时间为45-60分钟,每周两次至少12周,以最大限度地提高认知能力.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.9K
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.7K
相关概念视频
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Negative and Cognitive Symptoms of Schizophrenia
60
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
60
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147
